000 | 01265cam a2200169 4500500 | ||
---|---|---|---|
005 | 20250121083954.0 | ||
041 | _afre | ||
042 | _adc | ||
100 | 1 | 0 |
_aHajjaji, Nawale _eauthor |
700 | 1 | 0 |
_a Tredan, Olivier _eauthor |
245 | 0 | 0 | _aTriple-negative breast cancer: From biology to clinical practice |
260 | _c2022. | ||
500 | _a68 | ||
520 | _aTriple-negative breast cancers (TNBC) are a large heterogeneous group of pathological and biologically diverse carcinomas. TNBC may be categorized based on distinct genomic or transcriptional patterns and/or immune characteristics, and classified as basal-like, mesenchymal, and luminal androgen-receptor subtypes. They may be highly infiltrated by immune cells or devoid of them. Molecular alterations should be screened to help define the treatment. Thus, there is a need to adopt a comprehensive view of TNBC biology in order to tailor the therapeutic strategy with targeted agents, including novel antibody-drug conjugates or innovative immunotherapies. | ||
786 | 0 | _nInnovations & Thérapeutiques en Oncologie | Volume 8 | Special Issue 2 | 2022-12-02 | p. 5-11 | 2431-3203 | |
856 | 4 | 1 | _uhttps://shs.cairn.info/journal-innovations-therapeutiques-en-oncologie-2025-HS2-page-5?lang=en&redirect-ssocas=7080 |
999 |
_c504562 _d504562 |